EurekaMag
+ Translate
+ Most Popular
Advantages and disadvantages of bordeaux mixture and of lime-sulphur used on apples in the growing season
Observations on the Umaria marine bed
10 years of hearing conservation in the Royal Air Force
Chocolate crumb - dairy ingredient for milk chocolate
Effect of daily gelatin ingestion on human scalp hair
Comparison of rice bran and maize bran as feeds for growing and fattening pigs
The composition of pampas-grass (Cortaderia argentea.)
The Accraian Series:
The mechanism of the Liebermann-Burchard reaction of sterols and triterpenes and their esters
Cerebrovascular Doppler ultrasound studies (cv-Doppler)
Toria: PT-303 - first national variety
Hair growth promoting activity of tridax procumbens
Productivity of Pekin x Khaki Campbell ducks
A stable cytosolic expression of VH antibody fragment directed against PVY NIa protein in transgenic potato plant confers partial protection against the virus
Solar treatment of wheat loose smut
Swimmers itch in the Lake of Garda
Bactofugation and the Bactotherm process
The effects of prefrontal lobotomy on aggressive behavior in dogs
Visual rating scales for screening whorl-stage corn for resistance to fall armyworm
Breakdown of seamounts at the trench axis, viewed from gravity anomaly
Kooken; pennsylvania's toughest cave
Recovery of new dinosaur and other fossils from the Early Cretaceous Arundel Clay facies (Potomac Group) of central Maryland, U.S.A
Zubor horny (Bison bonasus) v prirodnych podmienkach Slovensku
The extended Widal test in the diagnosis of fevers due to Salmonella infection
Hair of the american mastodon indicates an adaptation to a semi aquatic habitat

Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)


Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)



Journal of the European Academy of Dermatology and Venereology: Jeadv 29(3): 452-456



ISSN/ISBN: 0926-9959

PMID: 24911993

DOI: 10.1111/jdv.12576

Following the establishment of the National Quality Registry for systemic psoriasis treatment (PsoReg), the two psoriasis outcome measurements, Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), are now integrated in clinical practice in Sweden. According to current guidelines, the initiation of a biological treatment should depend on a combination of the physician's (PASI) and the patients' assessment of the disease impact on a health-related quality of life measure (DLQI). To evaluate if either of the two measures, PASI or DLQI, is more strongly associated with initiation of biological therapy. The study is based on 2216 patients suffering from moderate to severe psoriasis who were biological naïve at enrolment to PsoReg. The relationship between the two measures PASI and DLQI and initiation of biological treatment (as outcome) were estimated by a logistic regression and a Cox proportional hazard's model with combinations of PASI and DLQI as independent variables. The adjusted regression models showed that patients with high PASI score and low DLQI score had a higher chance to receive biological treatment compared to patients with low PASI score and high DLQI score. The decision to initiate biological treatment is more strongly associated with PASI than with DLQI. However, since the DLQI reflects both socio-economic costs and patient suffering better than PASI, the relevance of the DLQI may be underestimated in clinical practice.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052456603

Download citation: RISBibTeXText

Related references

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. Journal of the European Academy of Dermatology and Venereology: Jeadv 28(3): 333-337, 2014

Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. Anais Brasileiros de Dermatologia 88(5): 760-763, 2013

PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. Journal of Dermatological Treatment 29(5): 481-486, 2018

Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after Treatment, in Patients with Skin and Nail Psoriasis. Skin Appendage Disorders 5(6): 344-349, 2019

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. Journal of Dermatological Treatment 28(6): 492-499, 2017

Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. Journal of dermatological treatment 31(5): 470-475, 2020

Understanding the Relationship Between Health Assessment Questionnaire-Disability Index (Haq-Di), Psoriasis Area Severity Index (Pasi), and Quality of Life (Qol) and its Influence on Cost-Effectiveness in Psoriatic Arthritis (Psa). Value in Health 18(7): A653, 2015

Responsiveness of the EuroQol 5-Dimension 3-Level instrument, Dermatology Life Quality Index (DLQI) and DLQI-Relevant for patients with psoriasis in the U.S.A. References 181(5): 1088-1090, 2019

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab. Acta Dermato-Venereologica 98(3): 335-339, 2018

Characteristics of patients with plaque psoriasis who have discordance between Psoriasis Area Severity Index and dermatology life quality index scores. Journal of the European Academy of Dermatology and Venereology: Jeadv 31(5): E269-E272, 2017

Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test. Dermatology and Therapy 9(3): 505-510, 2019

Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring. References 34(9): E484-E486, 2020

Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. Journal of Dermatological Treatment 28(8): 731-736, 2017

Dermatology Life Quality Index (DLQI) as a psoriasis referral triage tool. British Journal of Dermatology 177(4): e136-e137, 2017

Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Dermato-Venereologica 85(5): 409-413, 2005